ArticleInfectious diseases and therapy2023

Final Results from a Phase 2b Randomized, Placebo-Controlled Clinical Trial of RBX2660: A Microbiota-Based Drug for the Prevention of Recurrent Clostridioides difficile Infection.

Erik R Dubberke et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.